Generated by AI
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies and tissue-specific therapeutics for serious diseases, with an emphasis on AL amyloidosis, immune-mediated conditions, and select cancers. Immix Biopharma’s current pipeline is led by NXC-201, a BCMA-targeted CAR-T cell therapy being evaluated for AL amyloidosis and related plasma-cell disorders, and IMX-110, a tissue-specific therapeutic studied in solid tumors. The company also works on immune-dysregulated and inflammatory diseases through its proprietary therapeutic platforms. Immix Biopharma operates in the biotechnology sector, where its role is centered on advancing investigational treatments designed to address high-unmet-need conditions through cell therapy and precision drug delivery approaches. Founded in 2012 and headquartered in Los Angeles, California, Immix Biopharma is positioned as a development-stage company focused on translating specialized oncology and immunology research into clinical programs.
Website11400 West Olympic Boulevard
Los Angeles, CA, 90064
United States
The latest articles about IMMX.
Summary of Nov 2's posts. Generated by AI.
Summary of Sep 29's posts. Generated by AI.
Summary of Jul 20's posts. Generated by AI.
Investors talking about IMMX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.